Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease

Rory M.C. Abrams, Brian D. Kim, Desiree M. Markantone, Kaitlin Reilly, Alberto E. Paniz-Mondolfi, Melissa R. Gitman, S. Yoon Choo, Winona Tse, Jessica Robinson-Papp

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Abstract

There is concern that the global burden of coronavirus disease of 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection might yield an increased occurrence of Guillain-Barré syndrome (GBS). It is currently unknown whether concomitant SARS-CoV-2 infection and GBS are pathophysiologically related, what biomarkers are useful for diagnosis, and what is the optimal treatment given the medical comorbidities, complications, and simultaneous infection. We report a patient who developed severe GBS following SARS-CoV-2 infection at the peak of the initial COVID-19 surge (April 2020) in New York City and discuss diagnostic and management issues and complications that may warrant special consideration in similar patients.

Original languageEnglish
Pages (from-to)797-799
Number of pages3
JournalJournal of NeuroVirology
Volume26
Issue number5
DOIs
StatePublished - 1 Oct 2020

Keywords

  • Coronavirus-19
  • Guillain-Barré syndrome
  • Neuromuscular disorders
  • Polyneuropathy
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 disease'. Together they form a unique fingerprint.

Cite this